Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

INTERVIEW: Behind The Scenes Of Skyepharma's Financial Phoenix And Merger

Executive Summary

Skyepharma's outgoing CEO Peter Grant, has been masterminding the company's return to profitability for a decade. He looks back on how he negotiated pharma's financial waters and how that led to the company's merger with UK competitor Vectura.

You may also be interested in...



Vectura, Skyepharma To Form World Respiratory Leader

A UK-based global leader in respiratory therapies will be created by Vectura Group PLC's planned purchase of SkyePharma PLC in a friendly, all-stock deal to forge a combined group with estimated market capitalization of just over £1bn, joint sales of £153.9m and profits of around £50.5m.

SkyePharma Thoughts Turn To M&A And In-House Research After Financial Turnaround

With increasing revenues and profits the UK drug delivery firm SkyePharma could only dream of some years ago, CEO Peter Grant says he will consider investing in internal research and external M&A opportunities, in a measured way, to build a long-term product pipeline.

Another top exec leaves AstraZeneca

A second top AstraZeneca executive is to leave the company in as many weeks. James Ward-Lilley, currently head of AstraZeneca's respiratory, inflammation and autoimmunity product and portfolio strategy, and a 28-year veteran of the company, is to become CEO of Vectura, a small UK firm focused on lung disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel